News Articles for PYC Therapeutics

Perth biotech PYC Therapeutics will go to market seeking $653 million to advance four of its treatments through early trial stages and towards their first transaction.

While the sector has long been defined by clinical potential, the Q2 results reveal a definitive shift toward commercial maturity for some.

This week's appointments include Glen Chidlow, Gavin Bain, Greg Lilleyman, Tanya Brown, and Paul McClintock.

PYC Therapeutics has announced that Peter Coleman has been appointed non-executive chair, effective from the end of its annual general meeting on November 18.

This week's business appointments include Rohan Hockings, Karen Priest, Janelle Marr, and more.

Perth-based biotech company PYC Therapeutics has reappointed Rohan Hockings as its managing director, five days after he announced his resignation.

PYC Therapeutics has ducked into a trading halt, just two days after it was announced that its managing director had resigned.

Perth-based biotech company PYC Therapeutics is on the hunt for a full-time managing director, following the resignation of Dr Rohan Hockings.

Tim Goyder has sold his Mosman Park house for a record price.

Perth-based PYC Therapeutics is battling to complete its $146 million capital raising after a large shortfall from retail investors and a “liquidity” issue by one of its underwriters.

Nedlands-based biotech company PYC Therapeutics is rattling the tin for up to $146 million to fund the progression of four novel drug candidates.

Nedlands-based biotech company PYC Therapeutics has received approvals to start human trials over a drug candidate for kidney disease.

Perth biotech company PYC Therapeutics has hit another major milestone, gaining approval to move its first-in-class PYC-001 drug to human trials.

Business News has significantly overhauled the BN30 index, a proxy for the WA economy, with seven new additions, prompted by the exit of takeover targets MMA Offshore, APM and Decmil.

Perth biotech company PYC Therapeutics has hit a major milestone in the development of a first-in-class drug to treat a rare eye disease, recently receiving orphan drug designation from the US FDA.

PYC Therapeutics is rattling the tin for up to $74.6 million to fund the progress of its medical drug trials, including for blinding eye and polycystic kidney diseases.

Perth biotechnology company PYC Therapeutics will collaborate with Google to develop and host an artificial intelligence platform for precision medicines.

Nedlands-based biotechnology company PYC Therapeutics has raised $30 million to progress its series of drug trials.

The commercial side of life sciences may have reached a critical mass in WA.

Property developer Exal Group has bought a 31,100 square metre lot from a Chinese real estate group, as it progresses its plans for its project worth more than $500 million at the site.

40under40: The journey from an idea to an approved medication is as difficult as putting a person on the moon, Rohan Hockings says.

GenusPlus Group managing director David Riches was named First Amongst Equals at the 2022 40under40 Awards, ahead of a diverse cohort of Western Australia's young business leaders.

The developer is seeking community input before submitting its plans for the vacant site.

A company targeting treatment of blindness was announced as the WA Innovator of the Year on Wednesday night.

The recent $100 million sale of Agworld is a badge of success for WA tech but also reveals the sector's limitations.

Four companies including VeinTech and Vision Pharma have been selected as finalists in the Great for the State category at the Innovator of the Year Awards.

Our board moves wrap includes Jun Zhou, JunMei Xu, and Jason Haddock.

Our board moves wrap includes Scott Nicholas, Sophie Raven, David Flanagan, Dimitri Bacopanos, and Bernard Hockings.

Our board moves wrap includes Beau Nicholls, Blair Sergeant, Brendan Borg, and Michael Rosenblatt.

The rising fortunes of biotech company PYC Therapeutics have bolstered the wealth of its major shareholders, most notably chairman Alan Tribe.

The updated WA ‘rich list' shows the state's iron ore magnates are moving far ahead of people who made their money in other industries.

Today's board moves wrap includes Cliff Lawrenson, David Netherway, Emmanuel Correia, Sahm Nasseri, Kaggen Ausma, Andrew Barclay, Raymond Parry, and Emma Stein.

Today's board moves wrap includes Jason Bontempo, Alex McCulloch, Rodney Johns, Geoff Greenhill, Warwick Davies, John Klepec, Patrick Burke, David Frances, David Minchin, and Douglas Huey.

Biotech company PYC Therapeutics has sought funding for its lead drug development program that aims to treat childhood blindness.

Our weekly appointments wrap includes Sue Fletcher, Henry van der Westhuizen, Alec O'Connell, Louise-Marlena Tarrier, Danielle Norrish and Georgia Cameron.

Our board moves wrap includes Richard Monti, Kristie Young, Bryn Hardcastle, Rohan Hockings, Douglas Huey, Dale Schultz, Paul Summers, and Louie Simens.

The ASX has launched a technology index with 46 constituent companies and while several, such as Nearmap and ResApp Health, have a WA connection, none are based in Perth.

Dampier Gold has appointed Gavin Solomon as special advisor to the board of directors.

Biotech company Phylogica announced it had increased its shareholding in Vision Pharma to 90 per cent, following a $15 million investment using funds it had raised through a recent rights issue.

Biotech company Phylogica has announced plans to raise $26.8 million through a rights issue, fully underwritten by chairman and major shareholder Alan Tribe, with the proceeds used primarily to fund preclinicial studies for its leading drug molecule.